Publications

2026

Chi X, Yuan Y, and Lin R. (2026). BOP2-Comb: Bayesian Optimal Phase II Design for Optimizing Doses and Assessing Contribution of Components in Drug Combinations. Therapeutic Innovation & Regulatory Science. 60(1):127-138.

2025

Chi X, Lin R, and Yuan Y. (2025). COCA: a randomized Bayesian design integrating dose optimization and component contribution assessment for combination therapies. Biometrics. 81(2):ujaf077.

Yeboa DN, Li J, Lin R, …, Chi X, … (2025) Therapy, Safety, and Logistics of Preoperative vs Postoperative Stereotactic Radiation Therapy: A Preliminary Analysis of a Randomized Clinical Trial. JAMA Oncology.

Dasgupta P, Dagher S, Chi X, et al. (2025). Genomic determinants of the diffusely infiltrative gliomatosis cerebri phenotype. Journal of Neuro-Oncology. 176(1): 19.

Wang Y, Chi X, and Lin R. (2025). Three-Outcome Dual-Criterion Randomized Phase II Clinical Trial Design. The New England Journal of Statistics in Data Science.

2024

Chi X, Yuan Y, Yu Z, and Lin R. (2024). A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints. Biometrical Journal. 66(2): 2300122.

2022

Chi X, Yu Z, and Lin R. (2022). BOB: Bayesian optimal design for biosimilar trials with co-primary endpoints. Statistics in Medicine. 41(26): 5319 – 5334.